Active substance
Calcium carbonate
- SFDA 5
- US price lines 2
- NHS prices 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CALCINATE | 600 mg | Film-coated tablet · Oral use | 60 Tablet Container | SAR 30.00 | Generic · OTC | RIYADH PHARMA | Valid |
| CARBOSET 600 mg film-coated tablet | 600 mg | Film-coated tablet · Oral use | 50 Blister | SAR 25.00 | Generic · OTC | Alrai Pharmaceutical industry Co. (L.L.C) | Valid |
| CALCINATE 500 mg film-coated tablet | 500 mg | Film-coated tablet · Oral use | 30 Blister | SAR 9.10 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| CALTRATE 600 MG TAB. | 600 mg | Tablet · Oral use | 60 Tablet Container | SAR 20.30 | Generic · OTC | PFIZER | Withdrawn by MAH · Not Marketed |
| OS-CAL TAB 500MG | 500 mg | Tablet · Oral use | 30 Tablet Container | SAR 20.45 | NCE · OTC | PFIZER | Invalid · Not Marketed |
Indications — CHI Daman Drug Formulary
BARIATRIC SURGERY; BREAST CANCER EARLY HORMONAL-SUPPORTIVE CARE; BREAST CANCER MET. HORMONAL-SUPPORTIVE CARE; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDERS; HYPERPARATHYRODISM; HYPOPARATHYROIDISM; JUVENILE IDIOPATHIC ARTHRITIS (JIA); MATERNAL AND CHILD HEALTHCARE- SUPPLEMENTATION FOR MOTHER AND CHILD; MYASTHENIA GRAVIS; OSTEOPOROSIS; POMPE DISEASE (LOPD); PSORIATIC ARTHRITIS; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS-SUPPORTIVE CARE AND ADRS MANAGEMENT; SPINAL MUSCULAR ATROPHY - MAINTENANCE OF BONE HEALTH; VITAMIN D DEFICIENCY
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CALCIUM CARB 1,250 MG/5 ML SUS | $0.02037 | per ML | 23 Sep 2026 |
| US NADAC | CALCIUM CARBONATE 648 MG TAB | $0.00807 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Calcium carbonate 1.25g chewable tablets sugar free | £9.33 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Calcium carbonate 1.5g chewable tablets sugar free | £8.70 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Calcium carbonate 2.5g chewable tablets sugar free | £14.21 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 9 Apr 2019 PEPCID COMPLETE — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Combinations containing Calcium carbonate
- Ascorbic acid + calcium carbonate
- Calcium carbonate + calcium lactate gluconate
- Calcium carbonate + heavy magnesium carbonate
- Calcium carbonate + magnesium carbonate
- Ascorbic acid + calcium carbonate + calcium lactate gluconate
- Ascorbic acid + calcium carbonate + effervescent base
- Calcium carbonate + famotidine + magnesium hydroxide
- Calcium carbonate + magnesium hydroxide + sodium bicarbonate
- Calcium carbonate + sodium alginate + sodium bicarbonate
- Calcium carbonate + sodium alginate + sodium hydrogen carbonate
- Ascorbic acid + calcium carbonate + colecalciferol + pyridoxine
- Ascorbic acid + calcium carbonate + vitamin b6 + vitamin d3
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.